



FY2022

Financial Results

Reported Revenue Growth

+12.8%

Core Revenue Growth at CER

+3.5%

Reported Operating Profit Growth

+6.4%

Includes YoY impact of one-time gain
from FY2021 sale of diabetes portfolio

Core Operating Profit Growth at CER

+9.1%

Core Operating Profit Margin

29.5%

Increase of 1.6 percentage points from previous fiscal year

Reported EPS Growth

+38.8%

Core EPS Growth at CER

+13.9%

Free Cash Flow


¥446.2B

Excluding Nimbus upfront payment,
Free Cash Flow would be **¥837.3B**

Net Debt / Adjusted EBITDA

2.6x

(**2.3x** Excluding Nimbus
upfront payment)



Year-on-year sales growth rates are at CER.

Our extensive portfolio of **Growth & Launch Products** continued to drive growth.

Share of Total Revenue

40%

Growth at CER

+19%

Temporary headwinds in FY2023 from generic entrants and lower demand for coronavirus vaccines

Core Revenue

¥3,840B

Core Operating Profit

¥1,015B

Core EPS

¥434

Management Guidance at CER

Core Revenue

Low-single-digit % decline

Core Operating Profit

Low-10s % decline

Core EPS

Low-20s % decline

Forecasted annual dividend increase to

¥188 Per share in FY2023

Adopted progressive dividend policy of increasing or maintaining dividend each year

“ We have updated our capital allocation policy as a reflection of our deleveraging progress and our new phase of investment for growth and shareholder returns. We have adopted a progressive dividend policy of increasing or maintaining the dividend each year, and in FY2023 we intend to raise the dividend to underscore confidence in our future growth profile.”

Christophe Weber

President and Chief Executive Officer



This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2022 investor presentation (available at [takeda.com/investors/financial-results](https://www.takeda.com/investors/financial-results)), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2022 investor presentation (available at [takeda.com/investors/financial-results](https://www.takeda.com/investors/financial-results)) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.

"Nimbus upfront payment" refers to the portion of the 4.0 billion USD upfront payment to Nimbus Therapeutics, LLC paid in February 2023 (such portion totaling 3.0 billion USD) for the acquisition of Nimbus Lakshmi, Inc.

